Intraocular sustained-release delivery systems for triamcinolone acetonide

Pharmaceutical Research

Volumn 26, Issue 4, 2009, Pages 770-784

  Mansoor, Saffar ^a   Kuppermann, Baruch D ^a   Kenney, M Cristina ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Conjugates codrugs; Drug delivery system; Microcannulation; Ocular implants; Triamcinolone

Indexed keywords

AGENTS ACTING ON THE EYE; BUDESONIDE; CILIARY NEUROTROPHIC FACTOR; DEXAMETHASONE; ETHYLENE VINYL ACETATE COPOLYMER; FLUOCINOLONE ACETONIDE; FLUOROURACIL; FLUTEX; GANCICLOVIR; KENAQUART; MEDIDUR; MICROSPHERE; MITOMYCIN C; NT 501; ONCILON A; POLYVINYL ALCOHOL; RINETON; STEROID; SURODEX; TISSUE PLASMINOGEN ACTIVATOR; TRIAMCINOLONE ACETONIDE; TRICINOLON; TRIESENCE; TRIVARIS; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ABSENCE OF SIDE EFFECTS; AQUEOUS HUMOR; BIODEGRADABLE IMPLANT; BLINDNESS; CANNULA; CATARACTOGENESIS; CENTRAL RETINA VEIN OCCLUSION; CHALAZION; CHRONIC DISEASE; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RETENTION; DRUG SAFETY; DRUG TISSUE LEVEL; ENDOCRINE OPHTHALMOPATHY; ENDOPHTHALMITIS; EYE DISEASE; GLAUCOMA; HUMAN; IDIOPATHIC JUXTAFOVEAL TELANGIECTASIA; INTRAOCULAR PRESSURE; LENS IMPLANT; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; POSTOPERATIVE INFLAMMATION; PRIORITY JOURNAL; PSEUDOENDOPHTHALMITIS; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; RETINITIS; REVIEW; SCLERITIS; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; SUSTAINED DRUG RELEASE; UNSPECIFIED SIDE EFFECT; UVEITIS; VERNAL CONJUNCTIVITIS; VISUAL IMPAIRMENT; VITRECTOMY; VITREORETINOPATHY; VOGT KOYANAGI SYNDROME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CATHETERIZATION; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EYE; EYE DISEASES; HUMANS; INJECTIONS; MICROSPHERES; TRIAMCINOLONE ACETONIDE;

EID: 61449152762     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9812-z     Document Type: Review

References (110)

1. K. Kooner, T. Zimmerman, and M. Sharir. Textbook of ocular pharmacology. Lippincott-Raven, Philadelphia, 1997.
2. D. Argenti B. K. Jensen R. Hensel K. Bordeaux R. Schleimer C. Bickel D. Heald 2000 A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration J. Clin. Pharmacol. 40 770 780
3. K. Kreines I. C. Weinberg 1975 The selection of adrenocorticosteroid preparations Ohio State Med. J. 71 698
4. B. Jensen D. Argenti R. Hensel 2000 A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration J. Clin. Pharmacol. 40 770 780
5. A. Boyd I. G. Duguid T. E. Mandel 1992 Adhesion molecules are expressed in the human retina and choroid Curr. Eye Res. 11 Suppl 153 159
6. J. Veraart A. Sommer M. Neumann 1998 Evaluation of the vasoconstrictive effects of topical steroids by laser-Dopplerperfusion-imaging Acta Derm.-Venereol. 78 15 18
7. R. A. Adler S. A. Naumann A. Mansouri R. J. Krieg Jr. K. Latta K. M. Sanders 1994 Anti-proliferative effects of deflazacort on Nb2 cells as quantitated by formazan production Life Sci. 55 1823 831
8. J. B. Jonas I. Kreissig R. Degenring 2005 Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases Prog. Retin. Eye Res. 24 587 611
9. J. Sosnowski C. Stetter-Neel D. Cole J. P. Durham M. G. Mawhinney 1997 Protein kinase C mediated anti-proliferative glucocorticoid-sphinganine synergism in cultured Pollard III prostate tumor cells J. Urol. 158 269 274
10. T. A. Ciulla J. D. Walker D. S. Fong M. H. Criswell 2004 Corticosteroids in posterior segment disease: an update on new delivery systems and new indications Curr. Opin. Ophthalmol. 15 211 220
11. E. A. Felinski D. A. Antonetti 2005 Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy Curr. Eye Res. 30 949 957
12. M. Nauck G. Karakiulakis A. P. Perruchoud E. Papakonstantinou M. Roth 1998 Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells Eur. J. Pharmacol. 341 309 315
13. H. E. Grossniklaus J. X. Ling T. M. Wallace S. Dithmar D. H. Lawson C. Cohen V. M. Elner S. G. Elner P. Sternberg Jr 2002 Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization Mol. Vis. 8 119 126
14. J. McLaren A. Prentice D. S. Charnock-Jones S. A. Millican K. H. Muller A. M. Sharkey S. K. Smith 1996 Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids J. Clin. Invest. 98 482 489
15. A. Del Maschio A. Zanetti M. Corada Y. Rival L. Ruco M. G. Lampugnani E. Dejana 1996 Polymorphonuclear leukocyte adhesion triggers the disorganization of endothelial cell-to-cell adherens junctions J. Cell. Biol. 135 497 510
16. A. M. Joussen V. Poulaki W. Qin B. Kirchhof N. Mitsiades S. J. Wiegand J. Rudge G. D. Yancopoulos A. P. Adamis 2002 Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo Am. J. Pathol. 160 501 509
17. D. A. Antonetti E. B. Wolpert L. DeMaio N. S. Harhaj R. C. Scaduto Jr 2002 Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin J. Neurochem. 80 667 677
18. A. Wenzel C. Grimm M. W. Seeliger G. Jaissle F. Hafezi R. Kretschmer E. Zrenner C. E. Reme 2001 Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor Invest. Ophthalmol. Vis. Sci. 42 1653 1659
19. F. Ali. A review of diabetic macular edema. Digit. J. Ophthalmol. (2002).
20. R. Herrero-Vanrell M. F. Refojo 2001 Biodegradable microspheres for vitreoretinal drug delivery Adv. Drug Deliv. Rev. 52 5 16
21. J. V. Aukunuru G. Sunkara N. Bandi W. B. Thoreson U. B. Kompella 2001 Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor Pharm. Res. 18 565 572
22. N. J. Mangini, and B. G. Kennedy. Native and cultured human RPE express P-glycoprotein, ARVO Annual Meeting, 2002.
23. P. M. Hughes O. Olejnik J. E. Chang-Lin C. G. Wilson 2005 Topical and systemic drug delivery to the posterior segments Adv. Drug Deliv. Rev. 57 2010 2032
24. V. H. L. Lee, K. J. Pince, D. A. Frambach, and B. T. Martini. Drug delivery to the posterior segment. Oxford University Press, New York, 1998.
25. P. Quiroga A. Dominquez M. Jareno 1993 El tratamento de enfermedads medicas con triamcinolone intravitrea Arch. Doc. Esp. Oftalmol. 65 491 498
26. M. Bessler B. W. McCuen Y. Tano 1981 The lack of toxicity of intravitreally administered triamcinolone acetonide Am. J. Ophthalmol. 91 785 788
27. H. S. Chin T. S. Park Y. S. Moon J. H. Oh 2005 Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes Retina 25 556 560
28. C. M. Jermak J. T. Dellacroce J. Heffez G. A. Peyman 2007 Triamcinolone acetonide in ocular therapeutics Surv. Ophthalmol. 52 503 522
29. M. A. Cunningham J. L. Edelman S. Kaushal 2008 Intravitreal steroids for macular edema: the past, the present, and the future Surv. Ophthalmol. 53 139 149
30. R. Klein B. E. Klein S. E. Moss M. D. Davis D. L. DeMets 1984 The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema Ophthalmology 91 1464 1474
31. C. H. Meyer 2007 Current treatment approaches in diabetic macular edema Ophthalmologica 221 118 131
32. F. Bandello R. Pognuz A. Polito A. Pirracchio F. Menchini M. Ambesi 2003 Diabetic macular edema: classification, medical and laser therapy Semin. Ophthalmol. 18 251 258
33. B. Sander 2006 Diabetic macular edema evaluated by optical coherence tomography Acta. Ophthalmol. Scand. 84 90
34. M. Colucciello 2008 Intravitreal bevacizumab and triamcinolone acetonide combination therapy for exudative neovascular age-related macular degeneration: short-term optical coherence tomography results J. Ocul. Pharmacol. Ther. 24 15 24
35. J. A. Tielsch. Vision problems in the US: a report on blindness and vision impairment in adults age 40 and older, Prevent Blindness America. Schaumburg, IL: Prevent Blindness, 1994.
36. P. H. O. Olejnik 2005 Drug delivery strategies to treat age-related macular degeneration Adv. Drug Deliv. Rev. 57 1991 1993
37. L. P. Iu A. K. Kwok 2007 An update of treatment options for neovascular age-related macular degeneration Hong Kong Med. J. 13 460 470
38. J. S. Sunness G. S. Rubin C. A. Applegate N. M. Bressler M. J. Marsh B. S. Hawkins D. Haselwood 1997 Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity Ophthalmology 104 1677 1691
39. C. N. Singh D. A. Saperstein 2008 Combination treatment with reduced-fluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovascularization in macular degeneration Retina 28 789 793
40. A. Frimpong-Boateng, A. Bunse, F. Rufer, and J. Roider. Photodynamic therapy with intravitreal application of triamcinolone acetonide in age-related macular degeneration: functional results in 54 patients. Acta Ophthalmol. 1-5 (2008).
41. G. Weigert S. Michels S. Sacu A. Varga F. Prager W. Geitzenauer U. Schmidt-Erfurth 2008 Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study Br. J. Ophthalmol. 92 356 360
42. J. Bradley M. Ju G. S. Robinson 2007 Combination therapy for the treatment of ocular neovascularization Angiogenesis 10 141 148
43. U. M. Schmidt-Erfurth C. Pruente 2007 Management of neovascular age-related macular degeneration Prog. Retin. Eye Res. 26 437 451
44. U. M. Schmidt-Erfurth G. Richard A. Augustin W. G. Aylward F. Bandello B. Corcostegui J. Cunha-Vaz A. Gaudric A. Leys R. O. Schlingemann 2007 Guidance for the treatment of neovascular age-related macular degeneration Acta. Ophthalmol. Scand. 85 486 494
45. U. Schmidt-Erfurth M. Niemeyer W. Geitzenauer S. Michels 2005 Time course and morphology of vascular effects associated with photodynamic therapy Ophthalmology 112 2061 2069
46. U. Schmidt-Erfurth U. Schlotzer-Schrehard C. Cursiefen S. Michels A. Beckendorf G. O. Naumann 2003 Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor Invest. Ophthalmol. Vis. Sci. 44 4473 4480
47. M. C. Gillies J. M. Simpson W. Luo P. Penfold A. B. Hunyor W. Chua P. Mitchell F. Billson 2003 A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results Arch. Ophthalmol. 121 667 673
48. C. Durairaj, J. C. Shah, S. Senapati, and U. B. Kompella. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res (2008). doi: 10.1007/s11095-008-9728-7.
49. H. Kim K. G. Csaky L. Gravlin P. Yuan R. J. Lutz P. M. Bungay G. Tansey D. E. F. Monasterio G. K. Potti G. Grimes M. R. Robinson 2006 Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration Retina 26 523 530
50. B. C. Gilger E. Malok T. Stewart P. Ashton T. Smith G. J. Jaffe J. B. Allen 2000 Long-term effect on the equine eye of an intravitreal device used for sustained release of cyclosporine A Vet. Ophthalmol. 3 105 110
51. B. D. Kuppermann. Implants can deliver corticosteroids, pharmacologic agents, Retina Today, 2007, pp. 27-31.
52. B. D. Kuppermann M. S. Blumenkranz J. A. Haller G. A. Williams D. V. Weinberg C. Chou S. M. Whitcup 2007 Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema Arch. Ophthalmol. 125 309 317
53. S. K. Seah R. Husain G. Gazzard M. C. Lim S. T. Hoh F. T. Oen T. Aung 2005 Use of surodex in phacotrabeculectomy surgery Am. J. Ophthalmol. 139 927 928
54. A. C. Wadood A. M. Armbrecht P. A. Aspinall B. Dhillon 2004 Safety and efficacy of a dexamethasone anterior segment drug delivery system in patients after phacoemulsification J. Cataract. Refract. Surg. 30 761 768
55. G. J. Jaffe D. Martin D. Callanan P. A. Pearson B. Levy T. Comstock 2006 Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study Ophthalmology 113 1020 1027
56. J. L. Bourges C. Bloquel A. Thomas F. Froussart A. Bochot F. Azan R. Gurny D. BenEzra F. Behar-Cohen 2006 Intraocular implants for extended drug delivery: therapeutic applications Adv. Drug. Deliv. Rev. 58 1182 1202
57. P. A. Sieving R. C. Caruso W. Tao H. R. Coleman D. J. Thompson K. R. Fullmer R. A. Bush 2006 Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants Proc. Natl. Acad. Sci. U. S. A. 103 3896 3901
58. W. Tao 2006 Application of encapsulated cell technology for retinal degenerative diseases Expert Opin. Biol. Ther. 6 717 726
59. J. I. Lim R. A. Wolitz A. H. Dowling H. R. Bloom A. R. Irvine D. M. Schwartz 1999 Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis Am. J. Ophthalmol. 127 288 293
60. T. Yasukawa Y. Ogura Y. Tabata H. Kimura P. Wiedemann Y. Honda 2004 Drug delivery systems for vitreoretinal diseases Prog. Retin. Eye Res. 23 253 281
61. T. Yasukawa Y. Ogura E. Sakurai Y. Tabata H. Kimura 2005 Intraocular sustained drug delivery using implantable polymeric devices Adv. Drug Deliv. Rev. 57 2033 2046
62. T. J. Smith P. A. Pearson D. L. Blandford J. D. Brown K. A. Goins J. L. Hollins E. T. Schmeisser P. Glavinos L. B. Baldwin P. Ashton 1992 Intravitreal sustained-release ganciclovir Arch. Ophthalmol. 110 255 258
63. J. Y. Driot G. D. Novack K. D. Rittenhouse C. Milazzo P. A. Pearson 2004 Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period J. Ocul. Pharmacol. Ther. 20 269 275
64. T. A. Ciulla M. H. Criswell R. P. Danis M. Fronheiser P. Yuan T. A. Cox K. G. Csaky M. R. Robinson 2003 Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants Br. J. Ophthalmol. 87 1032 1037
65. N. R. Beeley J. M. Stewart R. Tano L. R. Lawin R. A. Chappa G. Qiu A. B. Anderson E. de Juan S. E. Varner 2006 Development, implantation, in vivo elution, and retrieval of a biocompatible, sustained release subretinal drug delivery system J. Biomed. Mater. Res. A. 76 690 698
66. S. Varner. Coatings: sustained-release drug delivery for retinal disease, MDDI Archive, 2005.
67. B. A. Booth L. Vidal Denham S. Bouhanik J. T. Jacob J. M. Hill 2007 Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications Drugs Aging 24 581 602
68. N. R. Beeley J. V. Rossi P. A. Mello-Filho M. I. Mahmoud G. Y. Fujii E. de Juan Jr. S. E. Varner 2005 Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal implant J. Biomed. Mater. Res. A. 73 437 444
69. T. Zhou H. Lewis R. E. Foster S. P. Schwendeman 1998 Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy J. Control. Release 55 281 295
70. D. D. Lewis. Controlled release of bioactive agents from lactide/glycolide polymers. In: M. Chasin and R. Langer (eds.), Biodegradable Polymers as Drug Delivery Systems, Biodegradable Polymers as Drug Delivery Systems, Marcel Dekker, New York, 1990.
71. L. J. Suggs A. G. Mikos 1996
72. A. A. Hincal S. Calis 2000
73. O. Felt-Baeyens S. Eperon P. Mora D. Limal S. Sagodira P. Breton B. Simonazzi L. Bossy-Nobs Y. Guex-Crosier R. Gurny 2006 Biodegradable scleral implants as new triamcinolone acetonide delivery systems Int. J. Pharm. 322 6 12
74. P. Breton D. Roy L. Marchal-Heussler C. Seguin P. Couvreur F. Lescure 1994
75. F. Lescure C. Seguin P. Breton P. Bourrinet D. Roy P. Couvreur 1994 Preparation and characterization of novel poly(methylidene malonate 2.1.2.)-made nanoparticles Pharm. Res. 11 1270 1277
76. S. Eperon L. Bossy-Nobs I. K. Petropoulos R. Gurny Y. Guex-Crosier 2008 A biodegradable drug delivery system for the treatment of postoperative inflammation Int. J. Pharm. 352 240 247
77. D. T. Tan S. P. Chee L. Lim A. S. Lim 1999 Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation Ophthalmology 106 223 231
78. A. S. Berger C. K. Cheng P. A. Pearson P. Ashton P. A. Crooks T. Cynkowski G. Cynkowska G. J. Jaffe 1996 Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy Invest. Ophthalmol. Vis. Sci. 37 2318 2325
79. T. A. Macky C. Oelkers U. Rix M. L. Heredia E. Kunzel M. Wimberly B. Rohrer C. E. Crosson J. Rohr 2002 Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate J. Med. Chem. 45 1122 1127
80. C. S. Yang J. A. Khawly D. P. Hainsworth S. N. Chen P. Ashton H. Guo G. J. Jaffe 1998 An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy Arch. Ophthalmol. 116 69 77
81. U. B. Kompella N. Bandi S. P. Ayalasomayajula 2003 Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression Invest. Ophthalmol. Vis. Sci. 44 1192 201
82. B. Khoobehi M. O. Stradtmann G. A. Peyman O. M. Aly 1991 Clearance of sodium fluorescein incorporated into microspheres from the vitreous after intravitreal injection Ophthalmic. Surg. 22 175 180
83. T. Moritera Y. Ogura N. Yoshimura Y. Honda R. Wada S. H. Hyon Y. Ikada 1992 Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy Invest. Ophthalmol. Vis. Sci. 33 3125 3130
84. R. Herrero-Vanrell L. Ramirez A. Fernandez-Carballido M. F. Refojo 2000. Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles, and sterilization process Pharm. Res. 17 1323 1328
85. H. Kimura Y. Ogura T. Moritera Y. Honda Y. Tabata Y. Ikada 1994 In vitro phagocytosis of polylactide microspheres by retinal pigment epithelial cells and intracellular drug release Curr. Eye Res. 13 353 360
86. T. Moritera Y. Ogura N. Yoshimura S. Kuriyama Y. Honda Y. Tabata Y. Ikada 1994 Feasibility of drug targeting to the retinal pigment epithelium with biodegradable microspheres Curr. Eye Res. 13 171 176
87. Y. Ogura H. Kimura 1995 Biodegradable polymer microspheres for targeted drug delivery to the retinal pigment epithelium Surv. Ophthalmol. 39 Suppl 1 S17 24
88. A. A. Veloso Jr. Q. Zhu R. Herrero-Vanrell M. F. Refojo 1997 Ganciclovir-loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus Invest. Ophthalmol. Vis. Sci. 38 665 675
89. T. Moritera Y. Ogura Y. Honda R. Wada S. H. Hyon Y. Ikada 1991 Microspheres of biodegradable polymers as a drug-delivery system in the vitreous Invest. Ophthalmol. Vis. Sci. 32 1785 1790
90. J. A. Cardillo A. A. Souza-Filho A. G. Oliveira 2006 Intravitreal Bioerudivel sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulness for the treatment of diabetic macular edema Arch. Soc. Esp. Oftalmol. 81 675 677
91. D. F. Martin D. J. Parks S. D. Mellow 1994 Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial Arch. Ophthalmol 112 1531 1539
92. G. J. Jaffe R. M. McCallum B. Branchaud C. Skalak Z. Butuner P. Ashton 2005 Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis Ophthalmology 112 1192 1198
93. G. J. Jaffe C. H. Yang H. Guo J. P. Denny C. Lima P. Ashton 2000 Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device Invest Ophthalmol. Vis. Sci. 41 3569 3575
94. D. F. Martin F. L. Ferris D. J. Parks R. C. Walton S. D. Mellow D. Gibbs N. A. Remaley P. Ashton M. D. Davis C. C. Chan R. B. Nussenblatt 1997 Ganciclovir implant exchange. Timing, surgical procedure, and complications Arch. Ophthalmol. 115 1389 1394
95. T. W. Olsen X. Feng K. Wabner S. R. Conston D. H. Sierra D. V. Folden M. E. Smith J. D. Cameron 2006 Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment Am. J. Ophthalmol. 142 777 787
96. L. D. Pizzarello F. A. Jakobiec A. J. Hofeldt M. M. Podolsky D. N. Silvers 1978 Intralesional corticosteroid therapy of chalazia Am. J. Ophthalmol. 85 818 821
97. E. Zamir R. W. Read R. E. Smith R. C. Wang N. A. Rao 2002 A prospective evaluation of subconjunctival injection of triamcinolone acetonide for resistant anterior scleritis Ophthalmology 109 798 805
98. A. A. Okada T. Wakabayashi Y. Morimura S. Kawahara E. Kojima Y. Asano T. Hida 2003 Trans-Tenon's retrobulbar triamcinolone infusion for the treatment of uveitis Br. J. Ophthalmol. 87 968 971
99. S. Singh V. Pal C. S. Dhull 2001 Supratarsal injection of corticosteroids in the treatment of refractory vernal keratoconjunctivitis Ind. J. Ophthalmol. 50 160 161
100. R. Ebner M. H. Devoto D. Weil M. Bordaberry C. Mir H. Martinez L. Bonelli H. Niepomniszcze 2004 Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone Br. J. Ophthalmol. 88 1380 1386
101. N. Benhamou P. Massin B. Haouchine F. Audren R. Tadayoni A. Gaudric 2003 Intravitreal triamcinolone for refractory pseudophakic macular edema Am. J. Ophthalmol. 135 246 249
102. F. Audren A. Erginay B. Haouchine R. Benosman J. Conrath J. F. Bergmann A. Gaudric P. Massin 2006 Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial Acta. Ophthalmol. Scand. 84 624 630
103. Z. F. Bashshur R. N. Ma'luf S. Allam F. A. Jurdi R. S. Haddad B. N. Noureddin 2004 Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion Arch. Ophthalmol. 122 1137 1140
104. M. S. Ip J. L. Gottlieb A. Kahana I. U. Scott M. M. Altaweel B. A. Blodi R. E. Gangnon C. A. Puliafito 2004 Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion Arch. Ophthalmol. 122 1131 1136
105. R. P. Danis T. A. Ciulla L. M. Pratt W. Anliker 2000 Intravitreal triamcinolone acetonide in exudative age-related macular degeneration Retina 20 244 50
106. L. M. Smithen R. F. Spaide 2004 Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis Am. J. Ophthalmol. 138 884 885
107. E. Rechtman V. D. Allen R. P. Danis L. M. Pratt A. Harris M. A. Speicher 2003 Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome Am. J. Ophthalmol. 136 739 741
108. R. E. Andrade C. Muccioli M. E. Farah R. B. Nussenblatt R. Belfort Jr 2004 Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome Am. J. Ophthalmol. 137 572 574
109. C. Furino T. Micelli Ferrari F. Boscia N. Cardascia N. Recchimurzo C. Sborgia 2003 Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy Retina 23 771 776
110. S. E. Burk A. P. Da Mata M. E. Snyder S. Schneider R. H. Osher R. J. Cionni 2003 Visualizing vitreous using Kenalog suspension J. Cataract. Refract. Surg. 29 645 651